Antibody ID	ANTI0QKXJZ
Antibody Name	EDB- (H16-K222R)-AcLys
Synonyms	EDB- (H16-K222R)-AcLys    Click to Show/Hide
Antigen Name	Vesicle-associated membrane protein 8 (VAMP8)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.51 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.54 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.14 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	21.11 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	714 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.56 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.76 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.19 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36.77 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4795 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.61 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.63 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13.55 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	27.57 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3082 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.71 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.85 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.16 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	21.18 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	157 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.71 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.36 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	530 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2090 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.97 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.16 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.72 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	66.27 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	155 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.98 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.86 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	20.44 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	32.4 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5317 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.17 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	61.1 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	134 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	17.64 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	33.52 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	786 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	793 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4320 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.17 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	46.04 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	55.05 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	83.68 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	126 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	34 ng/mL	Positive EDB expression (EDB+++/++)
Method Description	Calculated using four-parameter logistic model #203 with XLfit v4.9 (IDBS)
In Vitro Model	Normal	WI38-VA13 cells		CVCL_2759
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3449 ng/mL	Negative EDB expression (EDB-)
Method Description	Calculated using four-parameter logistic model #203 with XLfit v4.10 (IDBS)
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	96.35 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	161 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	357 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	416 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8031 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	109 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	202 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	227 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	404 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1884 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Ref 1	Calicheamicin derivatives and antibody drug conjugates thereof
Ref 2	Anti-EDB antibodies and antibody-drug conjugates